An arbitral tribunal ruled PM647 falls within Prime Medicine’s licensed field, confirming their right to develop and commercialize the AATD therapy without owing damages to Beam Therapeutics. The company will submit an IND/CTA for PM647 in Q3 2026 and expects initial clinical data in 2027.
The tribunal found PM647 within Prime Medicine’s licensed field and confirmed no breach of the 2019 collaboration agreement, eliminating any monetary damages owed to Beam Therapeutics and clearing legal obstacles for PM647 development.
PM647 leverages Prime Medicine’s universal liver lipid nanoparticle to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, achieving high editing efficiency and restoring the corrected protein isoform into the healthy human range in mouse models at clinically relevant doses.
Prime Medicine plans to file an IND and/or CTA for PM647 in the third quarter of 2026, with initial clinical data from the AATD program expected in 2027 as the therapy advances toward first-in-human trials.
With PM647’s rights secured, Prime Medicine can focus resources on advancing its AATD and Wilson Disease programs, leveraging the Prime Editing platform to target major genetic liver diseases and expand its curative therapy pipeline.
